Skip to content
DataLookout
Menu

NCT06245915

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Mar 31, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 15 words
    • Study sites: 9 to 8
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 130 to confirmed 37
    • Study sites revised (9)
    v8
  3. Minor Study description shortened, about 53 words
    • Study title shortened, about 1 word
    v7
  4. Notable Primary completion date: Feb 26, 2025 to Mar 31, 2026
    • Study sites: 7 to 9
    • Study completion date: May 31, 2027 to Jun 30, 2028
    v6
  5. Minor Study sites: 4 to 7v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Study sites: 2 to 4v4
  2. Minor Study sites: 1 to 2v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1 (Dose escalation): incidence of adverse events
Timeframe: From AB-2100 infusion up to 21 days post infusion
Phase 2 (Cohort expansion): Objective response rate (ORR)
Timeframe: From AB-2100 infusion up to 24 months post-infusion

Arms and interventions

AB-2100Experimental

Patients receive a single dose of AB-2100 intravenously on day 0. Patients may be assigned to receive conditioning chemotherapy prior to the infusion.

Biologicals: AB-2100

Sites

8 sites in 1 country